江蘇恒瑞醫藥股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） Jiangsu Hengrui Pharmaceuticals Co., Ltd. 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-005 江苏恒瑞医药股份有限公司 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月9日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市 ...

Core Viewpoint - The Hong Kong IPO market experienced a strong resurgence in 2025, with 114 companies completing listings and raising a total of HKD 285.3 billion, a 224% increase from HKD 88.1 billion in 2024, making it the largest IPO fundraising exchange globally [1][3]. Group 1: IPO Market Performance - The significant rebound in the IPO market is attributed to both the global liquidity environment and the concentrated demand from mainland companies seeking to raise funds in Hong Kong [1][3]. - The fundraising landscape in 2025 is characterized by a dominance of familiar types of listings, including A to H, spin-offs, and returning Chinese companies, which collectively contributed over 70% of the total fundraising [1][3]. Group 2: A to H Listings - A to H listings emerged as the absolute mainstay of fundraising in 2025, with 19 A-share companies successfully listing in Hong Kong, raising a total of HKD 140 billion, accounting for 49% of the total IPO fundraising [3]. - Notable A to H IPOs include CATL, which raised HKD 41 billion, followed by SANY Heavy Industry (HKD 15.3 billion), Seres (HKD 14.3 billion), and others, all contributing significantly to the overall fundraising [3]. Group 3: Spin-offs and Related Listings - In 2025, four companies completed spin-off listings, raising a total of HKD 34.9 billion, with Zijin Mining International leading at HKD 28.7 billion [3]. - Related companies, such as Innovation Industry and Conch Materials Technology, raised a combined HKD 6.8 billion, leveraging their parent company resources [3]. Group 4: Returning Chinese Companies - Three Chinese companies returned to Hong Kong for secondary listings, focusing on advanced sectors like smart driving and lidar, raising a total of HKD 13.9 billion [4]. - The trend of returning Chinese companies is expected to encourage more firms to consider dual listings in Hong Kong, enhancing market dynamics [4]. Group 5: Market Structure Changes - The fundraising structure has shifted significantly over the years, with familiar faces dominating the market in 2025, contrasting with the balanced new face listings seen in 2021-2022 [4]. - The proportion of familiar face listings surged in 2025, marking a reversal from the previous year's decline, driven by the resurgence of A to H listings [4]. Group 6: Market Outlook - The Hong Kong market serves as a crucial bridge between mainland and global capital, requiring both established players and new entrants to enhance market vitality [6]. - The expectation is for more high-quality unlisted entities, like Chery Automobile, to enter the market, bringing innovation and growth potential [6].

Core Viewpoint - The Hong Kong IPO market has shown a strong recovery in 2025, with 115 companies completing listings and raising a total of 285.3 billion HKD, a 224% increase compared to 88.1 billion HKD in 2024, making it the largest IPO fundraising exchange globally [1][4]. Group 1: IPO Market Performance - The top ten IPO projects accounted for 1,555 billion HKD, representing 55% of the total fundraising for the year [1][4]. - Notably, CATL led the IPOs with a fundraising amount of 41 billion HKD, marking the largest IPO in Hong Kong in nearly four years and the second largest globally in 2025 [2][5]. Group 2: A-Share Companies Going Public - A total of 19 A-share companies listed in Hong Kong, making up 17% of the total IPOs, but they raised 1,400 billion HKD, which is 49% of the total IPO fundraising in Hong Kong [3][6]. - The trend of A-share companies going public in Hong Kong is driven by the advantages of international capital access and financing convenience [3][6]. Group 3: Notable IPOs and Trends - Zijin Mining's spin-off, Zijin Gold International, raised 28.7 billion HKD, benefiting from favorable gold market conditions [3][7]. - The return of Chinese concept stocks to Hong Kong, exemplified by Pony.ai's 6.7 billion HKD IPO, indicates a trend of capital flow back to the Hong Kong market [3][7]. Group 4: Market Composition and Future Outlook - The top ten IPOs primarily consist of familiar names, with six being A to H listed A-share companies, two being spin-offs, and one being a returning Chinese concept stock, while Chery Automobile is the only new entrant [4][8]. - The Hong Kong market is expected to continue attracting high-quality new listings to enhance its market vitality and financing capabilities [4][8].

Group 1 - The top three companies with the highest short positions are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.81%, 18.09%, and 16.45% respectively [1][2] - The companies with the largest increase in short positions are Lens Technology (06613), Shangmei Co., Ltd. (02145), and Youran Dairy (09858), with increases of 2.38%, 0.97%, and 0.64% respectively [1][2] - The companies with the largest decrease in short positions are Sanhua Intelligent Control (02050), SenseTime-W (00020), and Ganfeng Lithium (01772), with decreases of -1.93%, -1.22%, and -1.06% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include Hengrui Medicine (01276) at 15.21%, ZTE Corporation (00763) at 14.26%, and Ping An Insurance (02318) at 14.10% [2] - The companies with the most significant increase in short ratios also include China Merchants Bank (03968) at 7.77% and Laopu Gold (06181) at 4.27% [2] - The companies with the most significant decrease in short ratios also include Zhongchuang Zhiling (00564) at 4.15% and Weichai Power (02338) at 4.93% [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating progress in its oncology pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, Chengdu Shengdi Pharmaceutical Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd., have been granted clinical trial approval for SHR-4394, HRS-5041 tablets, Zemeituosita tablets (SHR-2554), and Rivirolem tablets [1] - The specific focus of the clinical trials will be on the safety, tolerability, and efficacy of SHR-4394 or HRS-5041 in combination with anti-tumor treatment in participants with prostate cancer [1]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Group 1 - The core viewpoint of the article is to introduce the CSI Technology Advantage Growth 50 Strategy Index, which aims to provide investors with multi-factor strategy investment targets based on the technology sector [1] - The index selects stocks from the technology industry based on factors such as growth, innovation, value, low volatility, and quality, focusing on companies with high trading volumes [1] - The index is rebalanced quarterly, with a maximum weight of 10% and a minimum of 0.1% for individual stocks [2] Group 2 - The top ten constituent stocks of the index include leading companies in various technology sectors, with a combined weight of 30.93% for the top ten stocks [2][3] - The index is heavily weighted towards large-cap stocks, with 31 constituents having a market capitalization exceeding 100 billion yuan [3][4] - The index shows a significant focus on the electronics industry, while also maintaining weights in telecommunications, computing, and pharmaceuticals [3] Group 3 - The article presents the performance of various factors within the sample space, indicating that growth, consensus expectations, and low volatility factors exhibit strong stock selection effects [20] - The analysis includes a comparison of the Technology 50 Strategy Index with other technology and innovation indices, highlighting its historical performance and annual returns [20][22] - The Technology 50 Strategy Index has a cumulative return of 97.26% over the backtesting period, ranking third among six technology indices [23] Group 4 - The expected revenue growth for the Technology 50 Strategy Index in 2026 is projected at 33.65%, outperforming other technology indices [25][29] - The index employs 11 factors for stock selection, providing a comprehensive evaluation compared to other indices that focus on fewer factors [31][32] - The article emphasizes the importance of analyst consensus expectations as a forward-looking indicator for company performance [31]

Core Viewpoint - The company has received approval from the National Medical Products Administration for four drug clinical trials, focusing on prostate cancer-related multi-center, open-label Phase II clinical research [1] Drug Approval Summary - **SHR-4394 Injection**: - Indication: Prostate cancer - Cumulative R&D investment: 38.4 million yuan - No similar products approved domestically or internationally [1] - **HRS-5041 Tablets**: - A novel AR PROTAC small molecule for prostate cancer - Cumulative R&D investment: 92.66 million yuan - Potential to overcome drug resistance; no similar products available [1] - **Zemiglozole Tablets**: - EZH2 inhibitor, approved for market in 2025 - Cumulative R&D investment: 216.82 million yuan - Similar products expected to generate approximately 51 million USD in global sales by 2024 [1] - **Rivolumab Tablets**: - Second-generation AR inhibitor, approved in 2022 - Cumulative R&D investment: 696.72 million yuan - Similar products projected to achieve around 11.037 billion USD in global sales by 2024 [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-006 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司成都盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发的《受理 通知书》，公司富马酸立康可泮（HRS-5965）胶囊的药品上市许可申请获国家药 监局受理。现将相关情况公告如下： 一、药品的基本情况 药品名称：富马酸立康可泮胶囊 剂型：胶囊剂 受理号：CXHS2600014 申报阶段：上市 申请人：成都盛迪医药有限公司 拟定适应症（或功能主治）：治疗既往未接受过补体抑制剂治疗的阵发性睡 眠性血红蛋白尿症（PNH）成人患者。 二、药品的临床试验情况 此次申报上市，是基于一项在既往未接受过补体抑制剂治疗的 PNH 患者中进 行的关键研究（HRS-5965-301）。该研究是一项评估 HRS-5965 胶囊对比依库珠 单抗用于治疗既往未接受过补体抑制剂治疗的 PNH 患者的 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-005 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司成都盛迪 医药有限公司、上海恒瑞医药有限公司收到国家药品监督管理局（以下简称"国 家药监局"）核准签发关于注射用 SHR-4394、HRS-5041 片、泽美妥司他片 （SHR-2554）、瑞维鲁胺片的《药物临床试验批准通知书》，将于近期开展临床 试验。现将相关情况公告如下： 二、药物的其他情况 注射用 SHR-4394 是公司自主研发的一款治疗用生物制品，拟用于治疗前列 腺癌。经查询，国内外尚无同类产品获批上市。截至目前，注射用 SHR-4394 相 关项目累计研发投入约为 3,840 万元。 HRS-5041 片是公司开发的新型、高效、选择性的 AR PROTAC（雄激素受体- 蛋白降解靶向嵌合体）小分子，拟用于治疗前列腺癌。HRS-5041 片对野生型及 药物名称 注射用 SHR ...